米索硝唑增强洛莫司汀的细胞毒性：可能的治疗获益。
Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.
作者信息
Hirst D G, Brown J M, Hazlehurst J L
出版信息
Br J Cancer. 1982 Jul;46(1):109-16. doi: 10.1038/bjc.1982.172.
Abstract
Enhancement of CCNU cytotoxicity by misonidazole (MISO) was studied in three tumours and two normal tissues in the mouse. The 3 experimental tumours (SCCVII/St, EMT6 and KHT) showed very different sensitivities to CCNU alone, but MISO enhanced the cell killing in ech case. The effect was not always dose-modifying, so that the CCNU dose range for the greatest enhancement was different in each of the tumours. In all 3 tumours, enhancement increased with dose of MISO. The effect on two normal tissues, marrow (CFU-S) and testis (spermatogonia), was also investigated. Enhancement of marrow toxicity could be demonstrated only at CCNU doses greater than 12.5 mg/kg, so that at lower CCNU doses there was a therapeutic gain equal to the tumour enhancement ratio. The spermatogonia effect, however, showed enhancement by MISO similar to that seen in the tumours at all CCNU doses up to 20 mg/kg.
摘要
在小鼠的三种肿瘤和两种正常组织中研究了米索硝唑（MISO）对洛莫司汀（CCNU）细胞毒性的增强作用。三种实验性肿瘤（SCCVII/St、EMT6和KHT）对单独使用的CCNU表现出非常不同的敏感性，但MISO在每种情况下均增强了细胞杀伤作用。这种作用并不总是具有剂量修饰性，因此每种肿瘤中实现最大增强效果的CCNU剂量范围各不相同。在所有三种肿瘤中，增强作用均随MISO剂量的增加而增强。还研究了其对两种正常组织，即骨髓（CFU-S）和睾丸（精原细胞）的作用。仅在CCNU剂量大于12.5 mg/kg时才能证明骨髓毒性增强，因此在较低的CCNU剂量下，治疗获益等同于肿瘤增强率。然而，在高达20 mg/kg的所有CCNU剂量下，精原细胞效应显示MISO的增强作用与肿瘤中所见相似。
相似文献
1
Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.米索硝唑增强洛莫司汀的细胞毒性：可能的治疗获益。
Br J Cancer. 1982 Jul;46(1):109-16. doi: 10.1038/bjc.1982.172.
2
3
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.米索硝唑对洛莫司汀药代动力学的影响——小鼠化学增敏的主要机制
Br J Cancer. 1983 May;47(5):659-69. doi: 10.1038/bjc.1983.104.
4
In vivo combination of misonidazole and the chemotherapeutic agent CCNU.米索硝唑与化疗药物洛莫司汀的体内联合应用。
Br J Cancer. 1981 Mar;43(3):367-77. doi: 10.1038/bjc.1981.57.
5
Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations.2-硝基咪唑对亚硝基脲在皮下9L肿瘤模型中的化学增敏作用：药代动力学及构效关系考量
Int J Radiat Oncol Biol Phys. 1990 May;18(5):1043-50. doi: 10.1016/0360-3016(90)90439-q.
6
Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.小鼠肿瘤对洛莫司汀与米索硝唑及其他辐射增敏剂联合用药的反应。
Br J Cancer. 1982 Feb;45(2):272-81. doi: 10.1038/bjc.1982.43.
7
Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain.米索硝唑与环己亚硝脲：化学增敏及治疗增效药代动力学机制的进一步证据
Br J Cancer. 1984 May;49(5):579-85. doi: 10.1038/bjc.1984.92.
8
Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.亲电子药物增强洛莫司汀抗肿瘤作用的构效关系
Br J Cancer. 1982 Aug;46(2):249-59. doi: 10.1038/bjc.1982.190.
9
Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU.米索硝唑或甲硝唑预处理对RIF-1小鼠肉瘤对美法仑、环磷酰胺、苯丁酸氮芥和洛莫司汀反应的影响。
Br J Cancer. 1982 Mar;45(3):447-55. doi: 10.1038/bjc.1982.73.
10
Misonidazole-induced chemopotentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea toxicity in O6-methylguanine-DNA methyltransferase proficient (Mer+) and deficient (Mer-) cell lines.米索硝唑对O6-甲基鸟嘌呤-DNA甲基转移酶功能正常（Mer+）和缺陷（Mer-）细胞系中1-(2-氯乙基)-3-环己基-1-亚硝基脲毒性的化学增敏作用。
Cancer Res. 1986 Jun;46(6):2892-7.
引用本文的文献
1
Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma.自然减毒单纯疱疹病毒HF10对具有免疫活性的口腔癌模型的溶瘤活性。
Mol Ther Oncolytics. 2020 Dec 19;20:220-227. doi: 10.1016/j.omto.2020.12.007. eCollection 2021 Mar 26.
2
Formulation of objective indices to quantify machine failure risk analysis for interruptions in radiotherapy.用于量化放射治疗中断的机器故障风险分析的客观指标的制定。
J Appl Clin Med Phys. 2021 Jan;22(1):165-173. doi: 10.1002/acm2.13126. Epub 2020 Dec 16.
3
Comprehensive Exome Analysis of Immunocompetent Metastatic Head and Neck Cancer Models Reveals Patient Relevant Landscapes.免疫健全的转移性头颈癌模型的全外显子组分析揭示了与患者相关的情况。
Cancers (Basel). 2020 Oct 12;12(10):2935. doi: 10.3390/cancers12102935.
4
Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer.肿瘤膜泡疫苗增强抗PD1抗体在头颈部癌免疫检查点抑制剂耐药鳞状细胞癌模型中的疗效。
Vaccines (Basel). 2020 Apr 14;8(2):182. doi: 10.3390/vaccines8020182.
5
Oncolytic activity of HF10 in head and neck squamous cell carcinomas.HF10 在头颈部鳞状细胞癌中的溶瘤活性。
Cancer Gene Ther. 2020 Aug;27(7-8):585-598. doi: 10.1038/s41417-019-0129-3. Epub 2019 Sep 3.
6
Immune-relevant aspects of murine models of head and neck cancer.头颈部癌症的鼠模型中的免疫相关方面。
Oncogene. 2019 May;38(21):3973-3988. doi: 10.1038/s41388-019-0686-9. Epub 2019 Jan 29.
7
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.曲美替尼抑制MEK可通过调节头颈鳞状细胞癌的抗肿瘤免疫增强抗PD-L1抑制剂的疗效。
Oncoimmunology. 2018 Sep 21;8(1):e1515057. doi: 10.1080/2162402X.2018.1515057. eCollection 2019.
8
Oral squamous carcinoma cells promote macrophage polarization in an MIF-dependent manner.口腔鳞状细胞癌细胞以 MIF 依赖性方式促进巨噬细胞极化。
QJM. 2018 Nov 1;111(11):769-778. doi: 10.1093/qjmed/hcy163.
9
Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.探讨淋巴结转移形成过程中血管生成缺失的现象。
J Natl Cancer Inst. 2015 Jun 10;107(9). doi: 10.1093/jnci/djv155. Print 2015 Sep.
10
A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models.在两种不同的小鼠肿瘤模型中，康普他汀介导的外周血中性粒细胞浓度降低及其对该药物抗肿瘤活性的影响。
PLoS One. 2014 Oct 9;9(10):e110091. doi: 10.1371/journal.pone.0110091. eCollection 2014.
本文引用的文献
1
A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.正常小鼠骨髓细胞辐射敏感性的直接测量。
Radiat Res. 1961 Feb;14:213-22.
2
Duration of spermatogenesis in the mouse and timing of stages of the cycle of the seminiferous epithelium.小鼠精子发生的持续时间及生精上皮周期各阶段的时间安排。
Am J Anat. 1956 Nov;99(3):507-16. doi: 10.1002/aja.1000990307.
3
Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.放射增敏剂米索硝唑增强烷化剂的抗肿瘤活性
Cancer Res. 1980 Nov;40(11):4165-72.
4
In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.KHT肉瘤对放疗增敏剂与卡氮芥联合化疗的体内反应。
Br J Cancer. 1981 Jan;43(1):93-9. doi: 10.1038/bjc.1981.13.
5
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.抗癌药物与米索硝唑或甲硝唑在体内的相互作用：环磷酰胺和卡莫司汀。
Br J Cancer. 1980 Dec;42(6):871-80. doi: 10.1038/bjc.1980.335.
6
Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole.分配系数作为开发毒性低于米索硝唑的放射增敏剂的指导。
Radiat Res. 1980 Apr;82(1):171-90.
7
Structure-pharmacokinetic relationships for misonidazole analogues in mice.米索硝唑类似物在小鼠体内的结构-药代动力学关系
Cancer Chemother Pharmacol. 1981;6(1):39-49. doi: 10.1007/BF00253009.
8
Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.米索硝唑对RIF-1肿瘤对环磷酰胺反应的增强作用。
Br J Cancer. 1981 Aug;44(2):208-18. doi: 10.1038/bjc.1981.172.
9
Enhancement of the effect of cytotoxic drugs by radiosensitizers.放射增敏剂增强细胞毒性药物的作用。
Br J Cancer. 1981 Jun;43(6):756-66. doi: 10.1038/bjc.1981.113.
10
Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.细胞毒性药物与米索硝唑联合使用增强对Lewis肺癌和人胰腺癌异种移植瘤的细胞杀伤作用。
Br J Cancer. 1981 Apr;43(4):451-7. doi: 10.1038/bjc.1981.66.
Zotero 插件